

Serial No. 10/022,618

Atty. Docket No. LeA 35 010

RECEIVED
CENTRAL FAX CENTER

AUG 03 2006

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 1, 3-5, and 12-15 are pending in this application. Claims 9-11 were cancelled in the Reply and Amendment submitted on December 21, 2005. Claims 2 and 6-8 have been cancelled in the Reply and Amendment submitted on June 15, 2006.

Claims 1 and 15 have been amended. Support for the amendments may be found throughout the application as originally-filed and may be found, for example, on pages 10-18 of the specification.

These claim amendments and additions are made to clarify the subject matter therein; and these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Advisory Action

The Examiner stated that the proposed claim amendments raise new issues that would require further consideration and/or search.

Claims 1 and 15 have been amended, and now recite "color marked" reagents. This is the same claim language that was introduced in the Reply and Amendment submitted on December 21, 2005.

Applicants respectfully request entry of the amendments submitted in the Reply and Amendment submitted on June 15, 2006 as well as entry of the amendments provided in this reply, and Applicants respectfully request reconsideration and reexamination of the present application.

CONCLUSION

For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Ungar is invited to contact the undersigned counsel.

Serial No. 10/022,618


Atty. Docket No. LeA 35 010

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Date: August 3, 2006

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459



Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972